The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology and international markets. Core operating profit rose 33% to ¥229 billion.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human ...